Alkem Laboratories will hold an in-person analyst and institutional investor meeting with Sprucegrove Investments on July 6, 2026, in Mumbai. The meeting is intended to provide insights into the company's operations and performance. The schedule is subject to change due to exigencies on the part of the investor or the company.

The disclosure was made in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Manish Narang, President – Legal, Company Secretary & Compliance Officer, signed the intimation on June 29, 2026.

Meeting Details

Alkem Laboratories Ltd 's wholly owned subsidiary, Alkem Medtech Private Limited, has executed a First Supplementary Agreement to advance its acquisition of Occlutech Holding AG. The agreement, signed on June 26, 2026, involves the selling shareholders of the Switzerland-incorporated company. This strategic move aims to secure a controlling interest of at least 51% and up to 55% of the total issued equity share capital of Occlutech.

The transaction follows earlier disclosures made to the stock exchanges on February 13, 2026, and March 6, 2026, which outlined the initial intent to acquire the stake. The execution of the supplementary agreement modifies the original Share Purchase Agreement dated March 6, 2026. The development is part of Alkem Laboratories' broader strategy to expand its footprint through its subsidiary.

Key Transaction Details

The acquisition structure involves Alkem Medtech purchasing shares directly from the existing shareholders of Occlutech. The following table summarizes the key aspects of the agreement:

The disclosure was submitted to the BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer of Alkem Laboratories Limited. A copy of the disclosure has been made available on the company's website.